Uses of monoclonal antibody 8h9

Abstract

This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

What is claimed is: 
     
         1 . An antibody secreted by hybridoma 8H9. 
     
     
         2 . The antibody of  claim 1 , wherein the antibody comprises heavy chain Complementary Determining Regions that have amino acid sequences selected from the group consisting of SEQ ID NOs:29, 30, and 31. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody comprises light chain Complementary Determining Regions that have amino acid sequences selected from the group consisting of SEQ ID NOs:32, 33, and 34. 
     
     
         4 . The antibody of  claim 1 , wherein the antibody is 8H9 antibody. 
     
     
         5 . The antibody of  claim 1 , wherein the antibody further comprises a detectable label. 
     
     
         6 . The antibody of  claim 1 , wherein the antibody is further modified to comprise sequences from human antibody. 
     
     
         7 . A composition comprising the antibody of  claim 1 . 
     
     
         8 . A pharmaceutical composition comprising the antibody of  claim 1  and a pharmaceutically acceptable carrier.